Benitec Biopharma
BNTC
6 hedge funds and large institutions have $1.85M invested in Benitec Biopharma in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.
395% more capital invested
Capital invested by funds: $373K → $1.85M (+$1.47M)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$2.04M |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$52.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$33.8K |
| 4 |
Morgan Stanley
New York
|
+$23K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$676 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
-$10K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HCM
1
Highbridge Capital Management
New York
| $1.53M | +$2.04M | +3,023 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $137K | +$33.8K | +50 | +23% |
|
|
3
Morgan Stanley
New York
| $101K | +$23K | +34 | +21% |
|
|
WS
4
Wedbush Securities
Los Angeles,
California
| $40K | +$52.7K | +78 | New |
|
5
Renaissance Technologies
New York
| $27K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $8K | +$676 | +1 | +7% |
|
|
7
CIBC Private Wealth Group
Atlanta,
Georgia
| – | -$10K | -12 | Closed |
|
|
8
Bank of America
Charlotte,
North Carolina
| – | -$8K | -10 | Closed |
|
BNTC Hedge Fund Activity: Q2 2018 in Review
6 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q2 2018, worth a combined $1.85M — up 395% from $373K a quarter earlier.
Fund positioning in BNTC was balanced in Q2 2018: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 0 trimmed.
The largest buyer was Highbridge Capital Management, opening a new position worth an estimated $2.04M. The largest seller was CIBC Private Wealth Group, exiting entirely with an estimated $10K sold.
- 6 institutional investors held Benitec Biopharma (BNTC) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $1.85M of Benitec Biopharma stock for Q2 2018, up 395% quarter-over-quarter.
- 2 funds opened new Benitec Biopharma positions in Q2 2018 and 2 closed out, a net change of 0 holders.
- The largest Benitec Biopharma buyer in Q2 2018 was Highbridge Capital Management, an estimated $2.04M added.
- The largest Benitec Biopharma seller in Q2 2018 was CIBC Private Wealth Group, an estimated $10K sold.
Based on aggregated 13F filings for Q2 2018.